On January 2, 2018 Array BioPharma Inc. (Nasdaq: ARRY) reported that its Chief Executive Officer, Ron Squarer, will speak at the Annual J.P. Morgan Healthcare Conference in San Francisco (Press release, Array BioPharma, JAN 2, 2018, View Source;p=RssLanding&cat=news&id=2324433 [SID1234522813]). The public is welcome to participate in the conference through a webcast on the Array BioPharma website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Annual J.P. Morgan Healthcare Conference

Presenter: Ron Squarer, Chief Executive Officer, Array BioPharma

Date: Monday, January 8, 2018

Time: 4:00 p.m. Pacific Time

Location: Westin St. Francis Hotel, San Francisco

Webcast: View Source;p=irol-calendar

On January 2, 2018 Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or "the Company") reported that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 36th Annual J.P Morgan Healthcare Conference as follows (Press release, Eagle Pharmaceuticals, JAN 2, 2018, View Source [SID1234522797]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date:
Wednesday, January 10, 2018

Time:
4:30 p.m. Pacific Standard Time

Location: Westin St. Francis Hotel, San Francisco
Webcast:

View Source

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.eagleus.com, under the Investors Section.

On January 2, 2018 AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, reported that Paul C. Grint, M.D., Chief Executive Officer, will present a company overview at the 10th Annual Biotech Showcase, on Monday, January 8, 2018, at 9:30 a.m. PST, in San Francisco (Press release, AmpliPhi Biosciences, JAN 2, 2018, View Source [SID1234522812]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available on the Events and Presentations page in the Investor Relations section of AmpliPhi’s website at www.ampliphibio.com.

On January 2, 2018 ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported that Mark Enyedy, President and CEO, will present at the upcoming 36th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for 8:30am PT (11:30am ET) on January 10, 2018 (Press release, ImmunoGen, JAN 2, 2018, View Source [SID1234522798]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the presentation, Mr. Enyedy will be joined by other members of ImmunoGen’s management team for a question-and-answer session at 9:00am PT (12:00pm ET).

A webcast of the presentation and question-and-answer session will be accessible live through the "Investors" section of the Company’s website, www.immunogen.com; a replay will be available in the same location for approximately two weeks.

On January 2, 2018 Alkermes plc (NASDAQ: ALKS) reported that its corporate presentation will be webcast live at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2018 at 10:30 a.m. PT (1:30 p.m. ET/6:30 p.m. GMT) from the Westin St. Francis Hotel in San Francisco (Press release, Alkermes, JAN 2, 2018, View Source;p=RssLanding&cat=news&id=2324467 [SID1234522811]). The presentation will be followed by a question and answer session that will begin at 11:00 a.m. PT (2:00 p.m. ET/7:00 p.m. GMT). A webcast of both the presentation and question and answer session may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.